New Covid 19 treatment, page-242

"At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%," Merck said in a news release. "7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo treated patients (53,377). Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo."

This is great news if proven to be effective. Any medication that saves lives is worth cheering for.
However, have they trialed enough patients to prove efficacy? Could some of the statisticians comment on this?

"A short-term regimen of daily pills would aim to fight the virus early after diagnosis and prevent symptoms from developing after exposure".
What % of people diagnosed with Covid 19 actually end up in hospital or die? Is 385 patients in the treatment group and 377 in the control group enough to overcome bias from randomly allocating extra people to the treatment arm that would have got better without medication?